Increasing levels of pretreatment HIV drug resistance and safety concerns for dolutegravir use in women of reproductive age: a double setback

Use of dolutegravir-based first-line antiretroviral therapy (ART) in response to rising levels of pretreatment HIV drug resistance (PDR) to non-nucleoside reverse transcriptase inhibitors (NNRTIs) may be limited given safety concerns for birth defects in women of child-bearing potential. Pooled data